XML 29 R18.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

Exclusive License Agreement (Invizyne) | 6 Months Ended
--- | ---
Jun. 30, 2024
Exclusive License Agreement |
Exclusive License Agreement (Invizyne) | 10. Exclusive License Agreement (Invizyne) On April 19, 2019, Invizyne entered into a license agreement (the “License Agreement”) with The Regents of the University of California (“The Regents”) for patent rights and associated technology relating to the biosynthetic platform being developed by the Company. Certain individuals named as inventors of the Patent are also the founding stockholders of Invizyne. One of the founders of Invizyne was the head of the laboratory which was used in the research and development of the patents and associated technology subject to the agreement with The Regents. Under the License Agreement, Invizyne holds an exclusive license of the patent rights and a non-exclusive license for the associated technology to make, have made, use, have used, sell, have sold, offer for sale, and import licensed products in the field of use. Under the License Agreement, Invizyne paid an initial license fee and is to pay an annual license fee and royalties on net sales, a minimum annual royalty that is credited against the royalties on net sales, and a percentage of any sublicensing income. The net income royalty commences after the first commercial sale of a licensed product. At June 30, 2024 and 2023, there were no accrued royalties recorded. Under the License Agreement, Invizyne is required to achieve certain development milestones. Invizyne is obligated to make payments upon achievement of certain sales thresholds, as defined in the License Agreement. As of June 30, 2024 and 2023, the development milestones have been met. The following net sales milestone payments have not yet been incurred. The net sales milestones do not have a deadline and are listed below as of June 30, 2024.
| ● | A payment of $250,000 when a licensed product reaches $1,000,000 in cumulative net sales.
| ● | A payment of $350,000 when a second licensed product reaches $ 2,000,000 in cumulative net sales.
If Invizyne breaches the terms of the License Agreement, The Regents may terminate the License Agreement. Invizyne may terminate the License Agreement, in whole or in part as to a particular patent right, at any time by providing notice of termination to The Regents as defined in the License Agreement. Under the License Agreement, the Company issued 499,377 shares of common stock equity representing four percent of its shares as initial consideration. The Company agreed to issue additional shares of common stock to The Regents so that The Regents own no less than four percent of all outstanding common shares of the Company until the Company has received an aggregate amount of $5,000,000 from the sale of equity securities. The Company received equity funding of $5,000,000 as of June 2022. As such, the non-dilution provision of the License Agreement was fulfilled and no additional common shares will be issued.

X
- References No definition available. + Details
Name: | MDBH_DisclosureExclusiveLicenseAgreementInvizyneAbstract
Namespace Prefix: | MDBH_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Exclusive License Agreement [Text Block] + References No definition available. + Details
Name: | MDBH_ExclusiveLicenseAgreementTextBlock
Namespace Prefix: | MDBH_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration